Literature DB >> 34936843

Unique Physiological and Genetic Features of Ofloxacin-Resistant Streptomyces Mutants.

Kanata Hoshino1,2, Ryoko Hamauzu1, Hiroyuki Nakagawa3,4, Shinya Kodani5, Takeshi Hosaka1,2,6.   

Abstract

New antimicrobial agents are urgently needed to combat the emergence and spread of multidrug-resistant bacteria. Activating the cryptic biosynthetic gene clusters for actinomycete secondary metabolites can provide essential clues for research into new antimicrobial agents. An effective method for this purpose is based on drug resistance selection. This report describes interesting results for drug resistance selection using antibiotics that target DNA replication and can effectively potentiate secondary metabolite production by actinomycetes. Ofloxacin-resistant mutants were isolated from five different streptomycetes. Ofloxacin is an antibiotic that binds to DNA complexes and type II topoisomerase, causing double-stranded breaks in bacterial chromosomes. Physiological and genetic characterization of the mutants revealed that the development of ofloxacin resistance in streptomycetes leads to the emergence of various types of secondary metabolite-overproducing strains. In Streptomyces coelicolor A3(2), ofloxacin-resistant mutants that overproduced actinorhodin, undecylprodigiosin, or carotenoid were identified. An ofloxacin-resistant mutant that overproduces methylenomycin A, whose biosynthetic gene cluster is located on the endogenous plasmid, SCP1, also was isolated. These observations indicate that ofloxacin resistance activates biosynthetic genes on both chromosomes and endogenous plasmids. We also identified the mutations that are probably involved in the phenotype of ofloxacin resistance and secondary metabolite overproduction in S. coelicolor A3(2). Furthermore, we observed an interesting phenomenon in which several ofloxacin-resistant mutants overproduced antibiotics in the presence of ofloxacin. Based on these results, we present the unique physiological and genetic characteristics of ofloxacin-resistant Streptomyces mutants and discuss the importance and potential development of the new findings. IMPORTANCE The abuse or overuse of antibacterial agents for therapy and animal husbandry has caused an increased population of antimicrobial-resistant bacteria in the environment. Consequently, fewer effective antimicrobials are now available. Due to the depleted antibiotic pipeline, pandemic outbreaks caused by antimicrobial-resistant bacteria are deeply concerning, and the development of new antibiotics is now an urgent issue. Promising sources of antimicrobial agents include cryptic biosynthetic gene clusters for secondary metabolites in streptomycetes and rare actinomycetes. This study's significance is the development of an unprecedented activation method to accelerate drug discovery research on a global scale. The technique developed in this study could allow for simultaneous drug discovery in different countries, maximizing the world's microbial resources.

Entities:  

Keywords:  Streptomyces; ofloxacin; ofloxacin resistance; secondary metabolism

Mesh:

Substances:

Year:  2021        PMID: 34936843      PMCID: PMC8824270          DOI: 10.1128/aem.02327-21

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   5.005


  36 in total

1.  Novel approach for improving the productivity of antibiotic-producing strains by inducing combined resistant mutations.

Authors:  H Hu; K Ochi
Journal:  Appl Environ Microbiol       Date:  2001-04       Impact factor: 4.792

2.  Heterologous production of a new lasso peptide brevunsin in Sphingomonas subterranea.

Authors:  Shinya Kodani; Hikaru Hemmi; Yuto Miyake; Issara Kaweewan; Hiroyuki Nakagawa
Journal:  J Ind Microbiol Biotechnol       Date:  2018-09-06       Impact factor: 3.346

Review 3.  The Science of Antibiotic Discovery.

Authors:  Kim Lewis
Journal:  Cell       Date:  2020-03-19       Impact factor: 41.582

4.  Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2).

Authors:  S D Bentley; K F Chater; A-M Cerdeño-Tárraga; G L Challis; N R Thomson; K D James; D E Harris; M A Quail; H Kieser; D Harper; A Bateman; S Brown; G Chandra; C W Chen; M Collins; A Cronin; A Fraser; A Goble; J Hidalgo; T Hornsby; S Howarth; C-H Huang; T Kieser; L Larke; L Murphy; K Oliver; S O'Neil; E Rabbinowitsch; M-A Rajandream; K Rutherford; S Rutter; K Seeger; D Saunders; S Sharp; R Squares; S Squares; K Taylor; T Warren; A Wietzorrek; J Woodward; B G Barrell; J Parkhill; D A Hopwood
Journal:  Nature       Date:  2002-05-09       Impact factor: 49.962

5.  Induction of actinorhodin production by rpsL (encoding ribosomal protein S12) mutations that confer streptomycin resistance in Streptomyces lividans and Streptomyces coelicolor A3(2).

Authors:  J Shima; A Hesketh; S Okamoto; S Kawamoto; K Ochi
Journal:  J Bacteriol       Date:  1996-12       Impact factor: 3.490

6.  Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis.

Authors:  Haruo Ikeda; Jun Ishikawa; Akiharu Hanamoto; Mayumi Shinose; Hisashi Kikuchi; Tadayoshi Shiba; Yoshiyuki Sakaki; Masahira Hattori; Satoshi Omura
Journal:  Nat Biotechnol       Date:  2003-04-14       Impact factor: 54.908

7.  Genome sequence of the streptomycin-producing microorganism Streptomyces griseus IFO 13350.

Authors:  Yasuo Ohnishi; Jun Ishikawa; Hirofumi Hara; Hirokazu Suzuki; Miwa Ikenoya; Haruo Ikeda; Atsushi Yamashita; Masahira Hattori; Sueharu Horinouchi
Journal:  J Bacteriol       Date:  2008-03-28       Impact factor: 3.490

8.  Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype.

Authors:  Zhaogang Sun; Yuhui Xu; Yong Sun; Yi Liu; Xuxia Zhang; Hairong Huang; Chuanyou Li
Journal:  Microb Drug Resist       Date:  2014-12       Impact factor: 3.431

9.  A rifampicin resistance mutation in the rpoB gene confers ppGpp-independent antibiotic production in Streptomyces coelicolor A3(2).

Authors:  J Xu; Y Tozawa; C Lai; H Hayashi; K Ochi
Journal:  Mol Genet Genomics       Date:  2002-08-15       Impact factor: 3.291

Review 10.  New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters.

Authors:  Kozo Ochi; Takeshi Hosaka
Journal:  Appl Microbiol Biotechnol       Date:  2012-11-11       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.